Mandaviya calls for collaboration to eliminate vector borne diseases

Wacker to expand mRNA-based actives capacity at Halle, Germany

Company is investing more than €100 million in the expansion of the Halle site

Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection

Jubilant HollisterStier announces CAD 100 mn for Montreal facility

The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million

Zydus receives final approval from USFDA for Lacosamide injection

Lacosamide Injection is used to treat partial-onset seizures.

India’s first mRNA vaccine from Gennova gets DCGI approval

It is a two dose vaccine to be administered intramuscularly at 28 days apart

Balaxi Pharmaceuticals' Hyderabad factory to be operational by March 2024

This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg

R&D key for the growth of nation: Dr. Mandaviya

The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.

50%+ patients delay cataract surgeries in India: Survey

73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries

Merck presents positive results from phase 1/2 study evaluating V116

V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019